| Name | Title | Contact Details |
|---|
Fresno Surgical Hospital (FSH) is a fully-licensed, Joint Commission-accredited hospital that delivers award-winning surgical care and patient satisfaction. We are a physician-owned hospital that focuses solely on providing advanced, affordable surgical care. Each year, FSH serves approximately 12,000 patients in our Central California service area including: Fresno, Madera, Merced, Kings and Tulare Counties. Our patients enjoy a non-traditional, hotel-like setting and a commitment to quality care and patient satisfaction. Twenty-seven private inpatient suites give patients and their families an environment that promotes relaxation, comfort and healing. FSH was founded by two orthopedic surgeons, Alan H. Pierrot, MD and Thomas Thaxter, MD, who had a vision of improving healthcare. Originally named Fresno Surgery Center (FSC), the facility opened as an outpatient surgery center in 1984. Within the first year, FSC was in the top 10 percent of all freestanding outpatient surgery centers in the nation, based on the number of patients served. The center`s approach to patient service was also unique. The rare combination of compassion, hospitality and surgical excellence continues to be our distinguishing factor. We were the first facility in the United States to provide elective surgery and post-surgical care in a non-hospital setting. Overwhelming popularity among patients, surgeons and staff established FSC as the leader in the nationwide trend toward elective surgery facilities. In fact, we have consistently been recognized as a top performer both in the state of California and nationally.
DeRoyal manufactures quality healthcare products worldwide. DeRoyal is behind everything from the number one orthopedic hospital brand to online tools that power the medical industry. We keep innovating because it's part of our heritage.
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.
For over 35 years, Davis Vision, an award-winning specialty Vision Health Plan, has provided custom designed vision and eyecare programs to corporations, union trust funds and managed care organizations across the country.
SWISH Dental, with convenient throughout Austin, Texas, transforms the way dental care is done. SWISH is the premier practice for Austin dental care providing general, ortho, cosmetic, and family dentistry. Kick back, unwind, and experience complete co...